British drugmaker AstraZeneca Plc could resume trials for its experimental coronavirus vaccine next week, the Financial Times reported on Wednesday, citing people associated with the trials.
The London-listed firm had to pause global trials of its potential vaccine for COVID-19 after an unexplained illness in a participant, which sent its shares lower as the move was seen as dimming prospects for an early rollout.
AstraZeneca did not immediately respond to a Reuters request for comment.